Implementing corrective actions at Goa unit; stopped Digene production at the facility: Abbott

The drug regulatory body also advised doctors and healthcare professionals to carefully prescribe and educate their patients to discontinue the medicine's use and for reporting of any adverse drug reactions arising due to consumption of the said product. Goa FDA officials had conducted multiple inspections of the plant after the drug maker announced the recall of the antacid produced at the site.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0XIjzet
via IFTTT